Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
hepatitis b | — | D006509 | — |
chronic hepatitis b | EFO_0004239 | D019694 | B18.1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Hepatitis b | D006509 | — | — | 1 | 3 | 12 | 14 | — | 30 |
Hepatitis | D006505 | — | K75.9 | 1 | 3 | 12 | 14 | — | 30 |
Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | 3 | 9 | 14 | — | 27 |
Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 3 | 11 | 12 | — | 27 |
Chronic hepatitis | D006521 | — | K73.9 | 1 | 1 | 7 | 7 | — | 16 |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | 1 | — | 2 |
Fibrosis | D005355 | — | — | — | — | 1 | 1 | — | 2 |
Biliary liver cirrhosis | D008105 | — | K74.3 | — | — | — | 1 | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Virus diseases | D014777 | — | B34 | — | — | 1 | — | — | 1 |
Herpesviridae infections | D006566 | EFO_0007309 | B00.4 | — | — | 1 | — | — | 1 |
Hepatitis b virus | D006515 | — | — | — | — | 1 | — | — | 1 |
Drug common name | Telbivudine |
INN | telbivudine |
Description | Telbivudine is a pyrimidine 2'-deoxyribonucleoside that is the L-enantiomer of thymine. A synthetic thymidine nucleoside analogue with activity against HBV DNA polymerase. It has a role as an antiviral drug and an EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor. It is functionally related to a thymine. It is an enantiomer of a thymidine. |
Classification | Small molecule |
Drug class | antineoplastics; antivirals (zidovudine group) (exception: edoxudine) |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | Cc1cn([C@@H]2C[C@@H](O)[C@H](CO)O2)c(=O)[nH]c1=O |
PDB | — |
CAS-ID | 3424-98-4 |
RxCUI | — |
ChEMBL ID | CHEMBL374731 |
ChEBI ID | 63624 |
PubChem CID | 159269 |
DrugBank | DB01265 |
UNII ID | 2OC4HKD3SF (ChemIDplus, GSRS) |